As reported in Xconomy, Amgen and Watson have announced a pact to produce and sell cancer biosimilars together. The companies didn't say which drugs they would be targetting other than to say they wouldn't be going after Amgen's drugs.
Who does that leave? Roche's (Genetech's) Avastin? Herceptin? Rituxan?
“This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients,” Amgen and Watson said in their joint statement. The products that this team introduces will be sold under a joint label.
Let the Games begin. Teva, Samsung/Biogen, Merck, Pfizer, Sandoz can't be too far in the distance.....
Posted by Bruce Lehr Dec 19th 2011.